AZD-4017

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H33N3O3S
Molecular Weight	419.581
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCSC1=C(C=CC(=N1)N2CCC[C@@H](CC(O)=O)C2)C(=O)NC3CCCCC3

InChI

InChIKey=NCDZABJPWMBMIQ-INIZCTEOSA-N

InChI=1S/C22H33N3O3S/c1-2-13-29-22-18(21(28)23-17-8-4-3-5-9-17)10-11-19(24-22)25-12-6-7-16(15-25)14-20(26)27/h10-11,16-17H,2-9,12-15H2,1H3,(H,23,28)(H,26,27)/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H33N3O3S
Molecular Weight	419.581
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28923789 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/89a00d1f45ff0e3d4647dcf08a8b02e4.html | https://clinicaltrials.gov/ct2/show/NCT03111810

AZD4017, a 11β-hydroxysteroid dehydrogenase type 1 inhibitor, has been developed by AstraZeneca for the treatment of obesity, raised intraocular pressure (IOP) and type 2 diabetes. Inhibition of 11β-HSD1 is an attractive mechanism for the treatment of obesity and other elements of the metabolic syndrome. However, studies were discontinued due to safety and efficacy reasons. Besides, specific inhibition of 11β-HSD1 can decrease intracranial pressure and consequently treat patients with Idiopathic Intracranial Hypertension (IIH), thus AZD4017 participated in phase II clinical trials to treat this disease. IIH, also known as benign intracranial hypertension or pseudotumor cerebri, is a condition of unknown etiology characterized by elevated intracranial pressure (ICP) and papilledema. In addition, AZD4017 in combination with prednisolone participated in phase II clinical trials for patients with Iatrogenic Cushing's Disease. It was postulated that the adverse metabolic effects of prednisolone could be reduced by co-administration of AZD4017.

Originator

Approval Year

PubMed

Title	Date	PubMed
Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).	2012-06-28	22691057
Glucocorticoids and cardiovascular disease.	2007-11	17984234
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.	2007-09	17912154
The metabolic syndrome.	2005-04-20	15836891

Patents

Sample Use Guides

In Vivo Use Guide

Idiopathic intracranial hypertension: 400 mg of AZD4017 or placebo twice daily Iatrogenic Cushing's Disease: AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:30:52 GMT 2025` Edited by `admin` on `Mon Mar 31 21:30:52 GMT 2025`
Record UNII	3JL137394Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-4017

Common Name

English

AZD4017

Preferred Name

English

3-PIPERIDINEACETIC ACID, 1-(5-((CYCLOHEXYLAMINO)CARBONYL)-6-(PROPYLTHIO)-2-PYRIDINYL)-, (3S)-

Common Name

English

AZD 4017 [WHO-DD]

Common Name

English

Code System Code Type Description

FDA UNII

3JL137394Y